Response to Brandt, Bednarz-Knoll, Kleinheinz et al.
作者信息
Chaturvedi Anil K, Udaltsova Natalia, Engels Eric A, Katzel Jed A, Yanik Elizabeth L, Katki Hormuzd A, Lingen Mark W, Silverberg Michael J
机构信息
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Department of Oncology, Kaiser Permanente, San Francisco, CA, USA.
出版信息
J Natl Cancer Inst. 2020 Sep 1;112(9):970-971. doi: 10.1093/jnci/djaa075.
Abstract
摘要
相似文献
1
Response to Brandt, Bednarz-Knoll, Kleinheinz et al.对布兰特、贝德纳兹-克诺尔、克莱因海因茨等人的回应
J Natl Cancer Inst. 2020 Sep 1;112(9):970-971. doi: 10.1093/jnci/djaa075.
2
[HISTOCHEMICAL ASPECTS OF ORAL LEUKOPLAKIA].[口腔白斑的组织化学方面]
Arch De Vecchi Anat Patol. 1964 Nov;44:489-526.
3
ORAL LEUKOPLAKIA, CARCINOMA, AND THE PROSTHODONTIST.口腔白斑、癌与口腔修复医师
J Prosthet Dent. 1965 Mar-Apr;15:367-76. doi: 10.1016/0022-3913(65)90110-1.
4
Oral leukoplakia: review of the literature.口腔白斑：文献综述
J Oral Surg (Chic). 1957 Jan;15(1):40-9.
5
Leukoplakia and incidence of oral cancer.白斑与口腔癌发病率
J Oral Pathol Med. 1989 Jan;18(1):17. doi: 10.1111/j.1600-0714.1989.tb00725.x.
6
The role of nutrition in oral leukoplakia including a therapeutic trial of topical vitamin A.营养在口腔白斑中的作用，包括局部应用维生素A的治疗试验。
Ann Otol Rhinol Laryngol. 1961 Mar;70:102-17. doi: 10.1177/000348946107000107.
7
STUDIES IN ORAL LEUKOPLAKIAS. V. CLINICAL AND HISTOLOGIC SIGNS OF MALIGNANCY.口腔白斑病研究。五、恶性病变的临床及组织学特征
Acta Odontol Scand. 1963 Nov;21:407-14. doi: 10.3109/00016356309028203.
8
[Leukoplakia of the lips and the mouth mucosa].[唇部及口腔黏膜白斑病]
Dtsch Zahnarztl Z. 1970 Oct;25(10):961-4.
9
Risk factors for leukoplakia and malignant transformation to oral carcinoma: a leukoplakia cohort in Taiwan.口腔白斑及恶变至口腔癌的危险因素：台湾的一个口腔白斑队列研究
Br J Cancer. 2000 Jun;82(11):1871-4. doi: 10.1054/bjoc.2000.1208.
10
[Mild leukoplakia on the mouth mucosa].[口腔黏膜轻度白斑]
Vestn Dermatol Venerol. 1970 Oct;44(10):28-32.
本文引用的文献
1
RE: Oral Leukoplakia and Risk of Progression to Oral Cancer: A Population-Based Cohort Study.主题：口腔白斑与进展为口腔癌的风险：一项基于人群的队列研究。
J Natl Cancer Inst. 2020 Sep 1;112(9):968-969. doi: 10.1093/jnci/djaa074.
2
Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.厄洛替尼和口腔癌风险：厄洛替尼预防口腔癌（EPOC）随机临床试验。
JAMA Oncol. 2016 Feb;2(2):209-16. doi: 10.1001/jamaoncol.2015.4364.
3
Teaching moment: why promising biomarkers do not always translate into clinically useful tests.教学时刻：为何有前景的生物标志物并不总能转化为临床有用的检测方法。
J Clin Oncol. 2014 Feb 1;32(4):359-61. doi: 10.1200/JCO.2013.52.3076. Epub 2013 Dec 23.
4
From differences in means between cases and controls to risk stratification: a business plan for biomarker development.从病例与对照之间的均值差异到风险分层：生物标志物开发的商业计划。
Cancer Discov. 2013 Feb;3(2):148-57. doi: 10.1158/2159-8290.CD-12-0196. Epub 2013 Jan 8.
5
Treatment and follow-up of oral dysplasia - a systematic review and meta-analysis.口腔发育异常的治疗和随访 - 系统评价和荟萃分析。
Head Neck. 2009 Dec;31(12):1600-9. doi: 10.1002/hed.21131.
Zotero 插件